Dr. Sohur is a clinician in the Neuroscience and Pain Research Unit of Pfizer’s Worldwide Research & Development, in Cambridge, Massachusetts. He also is a part-time attending neurologist in the Division of Movement Disorders at Massachusetts General Hospital, and a junior faculty at Harvard Medical School in Boston. He grew up in the village of Espérance Trébuchet, Mauritius.
He received his Bachelors in Chemistry and Biology at Angelo State University, San Angelo, Texas, and his M.D. and Ph.D. degrees at Vanderbilt University, Nashville, Tennessee. Since 2001, Dr. Sohur has been at Harvard, where he completed his clinical training in Neurology with sub-specialty in Movement Disorders and then joined MGH. In January of this year, he transitioned to Pfizer, where he is helping conduct clinical trials in neurological disorders.
For the last 15 years, as a private citizen, Dr. Sohur has been developing ‘5/2035’, a comprehensive health policy blueprint that aims to curb type II diabetes in Mauritius from its current 15% prevalence to 5% by the year 2035 using a multi-sectoral approach. Around this tangible goal, ‘5/2035’ has the larger ambition of improving the overall nefarious effects of diabetes-associated chronic non-communicable diseases (CNCD are defined to include type II diabetes, cardiovascular disease, and stroke), and the entire Mauritian healthcare system and quality of life within the next generation. Importantly, ‘5/2035’ aligns itself to be a driver in the Mauritian economic engine by creating an exportable pragmatic evidence-based community health model to the rest of the world.